Literature DB >> 11000467

Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili.

F O Eko1, U B Mayr, S R Attridge, W Lubitz.   

Abstract

Bacterial ghosts are attractive for use as non-living vaccines and as carriers of heterologous antigens of vaccine relevance. Ghosts were prepared from Vibrio cholerae strains of O1 or O139 serogroup after growth under culture conditions, which favor or repress the production of toxin-coregulated pili (TCP). Immunoblotting confirmed the TCP status of these V. cholerae ghosts (VCG), which retained the cellular morphology and envelope sub-component profile of viable bacteria. Rabbits were immunized with VCGs prepared from O139 bacteria with TCP-positive or TCP-negative phenotypes and the resulting sera assayed for antibodies to lipopolysaccharide (LPS) and to TCP. Regardless of the TCP status of the VCG preparations used for immunization, all animals produced antibodies to LPS as demonstrated in bactericidal assays. These antibodies were probably responsible for the capacity of the antisera to confer passive immunity to challenge with the homologous O139 strain in the infant mouse cholera model (IMCM). Only following immunization with TCP-positive VCG, however, were antibodies to TCP generated, as judged by the potential of antisera to mediate protection against a challenge strain of heterologous serogroup.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000467     DOI: 10.1016/s0168-1656(00)00315-1

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  26 in total

1.  Online monitoring of Escherichia coli ghost production.

Authors:  W Haidinger; M P Szostak; W Jechlinger; W Lubitz
Journal:  Appl Environ Microbiol       Date:  2003-01       Impact factor: 4.792

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

4.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

5.  Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.

Authors:  Ulrike Beate Mayr; Christoph Haller; Wolfgang Haidinger; Alena Atrasheuskaya; Eugenij Bukin; Werner Lubitz; Georgy Ignatyev
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.

Authors:  Qing Pan; Roshan Pais; Adaugo Ohandjo; Cheng He; Qing He; Yusuf Omosun; J U Igietseme; F O Eko
Journal:  Vaccine       Date:  2015-02-17       Impact factor: 3.641

7.  A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.

Authors:  Eno E Ekong; Daniel N Okenu; Jayanti Mania-Pramanik; Qing He; Joseph U Igietseme; Godwin A Ananaba; Deborah Lyn; Carolyn Black; Francis O Eko
Journal:  FEMS Immunol Med Microbiol       Date:  2008-11-18

Review 8.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

9.  Escherichia coli ghost production by expression of lysis gene E and Staphylococcal nuclease.

Authors:  W Haidinger; U B Mayr; M P Szostak; S Resch; W Lubitz
Journal:  Appl Environ Microbiol       Date:  2003-10       Impact factor: 4.792

10.  Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine.

Authors:  Shakyra Richardson; Fnu Medhavi; Tayhlor Tanner; Stephanie Lundy; Yusuf Omosun; Joseph U Igietseme; Darin Carroll; Francis O Eko
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.